Literature DB >> 23794089

Dual role of PPAR-γ in induction and expression of behavioral sensitization to cannabinoid receptor agonist WIN55,212-2.

Leili Enayatfard1, Farzaneh Rostami, Sanaz Nasoohi, Shahrbanoo Oryan, Abolhassan Ahmadiani, Leila Dargahi.   

Abstract

Behavioral sensitization (B.S.) is a pathophysiological animal model for stimulant-induced psychosis and addiction. Accumulated evidence indicates that inflammatory processes are involved in psychostimulants effects in the CNS. Cannabinoids like WIN55,212-2 act as potential activators of PPAR-γ and affects the inflammatory status of the CNS. The purpose of this study is to determine PPAR-γ role in induction and expression of B.S. and the coincident inflammatory responses developed by WIN55,212-2 (WIN). Using open-field test, locomotor activity was monitored in animals treated with intraperitoneal low-dose WIN single or repeated injections. Concurrent striatal COX-2 and TNF-α levels and PPAR-γ activity were determined by immunoblotting assay. Effects of concomitant chronic or acute PPAR-γ pharmacological inhibition (with GW9662) were then investigated on behavioral and biochemical variables. WIN enhanced locomotor activity and while administered chronically augmented cytosolic COX-2 and TNF-α and also PPAR-γ nuclear levels. GW9662 co-administration completely prevented the induction of sensitizing effects of chronic WIN and altered the inflammatory responses. However, the expression of B.S. was intensified with GW9662 as assessed by increased locomotion after WIN challenge following 48 h withdrawal. Neuroinflammation and locomotor excitability in animals received just a single-dose WIN were also escalated with GW9662. Our findings conclude that PPAR-γ could play different key roles during B.S. development by WIN. Although PPAR-γ is mostly known for neuroprotective and anti-inflammatory effects, our data indicate that it mediates the B.S. induction by chronic WIN. However, while the B.S. was induced, PPAR-γ could play a homeostatic role opposing the expressed B.S. escalation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23794089     DOI: 10.1007/s12017-013-8238-x

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  56 in total

Review 1.  A range of research-based pharmacotherapies for addiction.

Authors:  C P O'Brien
Journal:  Science       Date:  1997-10-03       Impact factor: 47.728

Review 2.  The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke.

Authors:  Alessandro Pini; Guido Mannaioni; Domenico Pellegrini-Giampietro; Maria Beatrice Passani; Rosanna Mastroianni; Daniele Bani; Emanuela Masini
Journal:  Curr Drug Targets       Date:  2012-06       Impact factor: 3.465

Review 3.  PPAR-gamma: a nuclear receptor with affinity for cannabinoids.

Authors:  Sumner Burstein
Journal:  Life Sci       Date:  2005-08-19       Impact factor: 5.037

4.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

Review 5.  Nicotine and behavioral sensitization.

Authors:  Danyan Mao; Daniel S McGehee
Journal:  J Mol Neurosci       Date:  2009-08-11       Impact factor: 3.444

Review 6.  Sensitization processes in drug addiction.

Authors:  Louk J M J Vanderschuren; R Christopher Pierce
Journal:  Curr Top Behav Neurosci       Date:  2010

7.  Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ.

Authors:  Huizhi Du; Xiaolei Chen; Jian Zhang; Chu Chen
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

8.  Cannabinoids and PPARalpha signalling.

Authors:  Y Sun; S P H Alexander; D A Kendall; A J Bennett
Journal:  Biochem Soc Trans       Date:  2006-12       Impact factor: 5.407

9.  Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment.

Authors:  Nico Wegener; Michael Koch
Journal:  Brain Res       Date:  2008-12-03       Impact factor: 3.252

Review 10.  Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence.

Authors:  Bernard Le Foll; Patricia Di Ciano; Leigh V Panlilio; Steven R Goldberg; Roberto Ciccocioppo
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

View more
  4 in total

1.  PPARγ agonism attenuates cocaine cue reactivity.

Authors:  William R Miller; Robert G Fox; Sonja J Stutz; Scott D Lane; Larry Denner; Kathryn A Cunningham; Kelly T Dineley
Journal:  Addict Biol       Date:  2016-11-11       Impact factor: 4.280

Review 2.  Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Authors:  Natalie E Zlebnik; Joseph F Cheer
Journal:  Annu Rev Neurosci       Date:  2016-02-24       Impact factor: 12.449

3.  The Cannabinoid Receptor Agonist, WIN-55212-2, Suppresses the Activation of Proinflammatory Genes Induced by Interleukin 1 Beta in Human Astrocytes.

Authors:  Jerel Adam Fields; Mary K Swinton; Patricia Montilla-Perez; Eugenia Ricciardelli; Francesca Telese
Journal:  Cannabis Cannabinoid Res       Date:  2020-12-31

Review 4.  Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System.

Authors:  Ana Lago-Fernandez; Sara Zarzo-Arias; Nadine Jagerovic; Paula Morales
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.